跳至主要内容
临床试验/NL-OMON37250
NL-OMON37250已完成2 期

Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor - CD4+ donor lymphocytes

eids Universitair Medisch Centrum0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Age > 18 years
  • Patients with AML, myelodysplasia , ALL, CML in accelerated phase or blastic transformation, CLL, MM or (non) Hodgkin lymphoma, who underwent an allo-SCT with an unrelated 10/10 matched donor (matched for HLA-A, B, C, DR and DQ)
  • Life expectation of > 3 months
  • WHO performance status of 0, 1 or 2
  • Written informed consent according to the rules and regulations of the Leiden University Medical Center.

排除标准

  • Use of systemic immunosuppressive treatment (due to GVHD)
  • Acute GVHD of the skin > grade 2 or progressive acute GVHD
  • Progressive disease needing cytoreductive treatment
  • Any concomitant disease preventing the safe administration of donor lymphocytes
  • Severe psychological disturbances
  • Severely limited life expectation due to diseases other than the malignancy
  • Very high risk disease preceding allo-SCT for which already unselected DLI is planned to be given 3 months after allo-SCT.

研究者

相似试验